Fulltext

Surveillance of Transmitted Drug-Resistant HIV Among Young Pregnant Women in Ouagadougou, Burkina Faso

Somda, Antoine ; Sangare, Lassana ; Soro, Monique ; Yameogo, Saydou ; Bazie, Babou ; Bigirimana, Françoise ; Bertagnolio, Silvia ; Peeters, Martine ; Mouacha, Fatima ; Rivera, Ana Maria ; Jordan, Michael R. ; Sanou, Marie-Joseph

In: Clinical Infectious Diseases, 2012, vol. 54, p. S317-S319

Add to personal list
    Title
    • Surveillance of Transmitted Drug-Resistant HIV Among Young Pregnant Women in Ouagadougou, Burkina Faso
    Author
    • Somda, Antoine. Ministry of Health/BFA, HIV Surveillance
    • Sangare, Lassana. Ministry of Health-LNR HIV
    • Soro, Monique. Ministry of Health-LNR HIV
    • Yameogo, Saydou. Ministry of Health-LNR HIV
    • Bazie, Babou. World Health Organization, Ouagadougou, Burkina Faso
    • Bigirimana, Françoise. World Health Organization, Ouagadougou, Burkina Faso
    • Bertagnolio, Silvia. World Health Organization, Geneva, Switzerland
    • Peeters, Martine. UMI233, Institut de Recherche pour le Development and Université de Montpellier 1, France
    • Mouacha, Fatima. Tufts University School of Medicine, Boston, Massachusetts
    • Rivera, Ana Maria. Tufts University School of Medicine, Boston, Massachusetts
    • Jordan, Michael R.. World Health Organization, Geneva, Switzerland
    • Sanou, Marie-Joseph. Ministry of Health/BFA, HIV Surveillance
    Document Type
    • Postprint
    Language
    • English
    Published in
    • Clinical Infectious Diseases, 2012, vol. 54, p. S317-S319. Oxford University Press
    Other Version
    Classification
    • Health
    OAI-PMH Identifier
    • oai:doc.rero.ch:293966
    Summary
    Burkina Faso began rapid antiretroviral therapy (ART) scale-up in 2003 and by December 2009, 26 448 individuals were on treatment. With rapid scale-up of ART, some degree of human immunodeficiency virus transmitted drug resistance (TDR) is inevitable. Following World Health Organization methods, between June 2008 and July 2009, Burkina Faso assessed TDR in primigravid pregnant women aged <25 years attending antenatal care clinics in Ouagadougou, Burkina Faso. TDR was classified as moderate (5%-15%) for both nucleoside reverse-transcriptase inhibitors and nonnucleoside reverse-transcriptase inhibitors. The observed moderate TDR in Ouagadougou is a cause for concern and calls for closer monitoring of Burkina Faso's ART program